Dofetilide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dofetilide" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

6doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

1web.archive.org

1^st place

1europa.eu

68^th place

117^th place

1pfizer.com

low place

doi.org

Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–786. doi:10.1592/phco.20.9.776.35208. PMID 10907968. S2CID 19897963.
Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, et al. (November 2008). "Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter". Journal of Interventional Cardiac Electrophysiology. 23 (2): 111–115. doi:10.1007/s10840-008-9290-6. PMID 18688699. S2CID 25162347.
Lenz TL, Hilleman DE (November 2000). "Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter". Drugs of Today. 36 (11): 759–771. doi:10.1358/dot.2000.36.11.601530. PMID 12845335.
Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, et al. (September 1999). "Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group". The New England Journal of Medicine. 341 (12): 857–865. doi:10.1056/NEJM199909163411201. PMID 10486417.
Roukoz H, Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Review of Cardiovascular Therapy. 5 (1): 9–19. doi:10.1586/14779072.5.1.9. PMID 17187453. S2CID 11255636.
Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW (1992). "Dofetilide, a novel class III antiarrhythmic agent". Journal of Cardiovascular Pharmacology. 20 (Suppl 2): S96–105. doi:10.1097/00005344-199220002-00015. PMID 1279316.

europa.eu

ema.europa.eu

Wathion N (2004-04-13). "Public Statement on Tikosyn (dofetilide): Voluntary Withdrawal of the Marketing Authorisation in the European Union" (PDF). European Agency for the Evaluation of Medicinal Products. Archived from the original (PDF) on 2017-10-13. Retrieved 2015-01-03.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

fda.gov

"Information for Tikosyn (dofetilide)". US Food and Drug Administration. 2016-03-09.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–786. doi:10.1592/phco.20.9.776.35208. PMID 10907968. S2CID 19897963.
Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, et al. (November 2008). "Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter". Journal of Interventional Cardiac Electrophysiology. 23 (2): 111–115. doi:10.1007/s10840-008-9290-6. PMID 18688699. S2CID 25162347.
Lenz TL, Hilleman DE (November 2000). "Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter". Drugs of Today. 36 (11): 759–771. doi:10.1358/dot.2000.36.11.601530. PMID 12845335.
Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, et al. (September 1999). "Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group". The New England Journal of Medicine. 341 (12): 857–865. doi:10.1056/NEJM199909163411201. PMID 10486417.
Roukoz H, Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Review of Cardiovascular Therapy. 5 (1): 9–19. doi:10.1586/14779072.5.1.9. PMID 17187453. S2CID 11255636.
Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW (1992). "Dofetilide, a novel class III antiarrhythmic agent". Journal of Cardiovascular Pharmacology. 20 (Suppl 2): S96–105. doi:10.1097/00005344-199220002-00015. PMID 1279316.
Walker DK, Alabaster CT, Congrave GS, Hargreaves MB, Hyland R, Jones BC, et al. (April 1996). "Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data". Drug Metabolism and Disposition. 24 (4): 447–455. PMID 8801060.

pfizer.com

labeling.pfizer.com

"TIKOSYN® (dofetilide)". Pfizer.

semanticscholar.org

api.semanticscholar.org

Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–786. doi:10.1592/phco.20.9.776.35208. PMID 10907968. S2CID 19897963.
Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, et al. (November 2008). "Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter". Journal of Interventional Cardiac Electrophysiology. 23 (2): 111–115. doi:10.1007/s10840-008-9290-6. PMID 18688699. S2CID 25162347.
Roukoz H, Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Review of Cardiovascular Therapy. 5 (1): 9–19. doi:10.1586/14779072.5.1.9. PMID 17187453. S2CID 11255636.

web.archive.org

Wathion N (2004-04-13). "Public Statement on Tikosyn (dofetilide): Voluntary Withdrawal of the Marketing Authorisation in the European Union" (PDF). European Agency for the Evaluation of Medicinal Products. Archived from the original (PDF) on 2017-10-13. Retrieved 2015-01-03.